Cargando…
Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza
BACKGROUND: Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a selective and reversible antagonist of C-X-C chemokine receptor 2, decreases neutrophil activation and transmigration to areas of inflammation. This study evaluated the efficacy...
Autores principales: | Madan, Anuradha, Chen, Shuguang, Yates, Phillip, Washburn, Michael L, Roberts, Grace, Peat, Andrew J, Tao, Yu, Parry, Michael F, Barnum, Otis, McClain, Micah T, Roy-Ghanta, Sumita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483311/ https://www.ncbi.nlm.nih.gov/pubmed/31041358 http://dx.doi.org/10.1093/ofid/ofz163 |
Ejemplares similares
-
The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
por: Miller, Bruce E., et al.
Publicado: (2015) -
Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza
por: Roberts, Grace, et al.
Publicado: (2019) -
The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers
por: Miller, Bruce E., et al.
Publicado: (2014) -
Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects
por: Jittamala, Podjanee, et al.
Publicado: (2014) -
CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin
por: Keir, Holly R., et al.
Publicado: (2020)